Bergen Brunswig
Executive Summary
Write off of $505 mil. on Bergen's long-term care pharmacy provider PharMerica recorded in fiscal fourth quarter recognizes that "the price that we paid for this business was too high," the company said during a Nov. 3 conference call. Bergen completed the acquisition, valued at about $1.4 bil. including assumption of debt, in April 1999. The write off was based on a decline in gross profit margins to around 35%. The company's "outlook is that those gross profit margins are not going to go back up to the historical 40% range," Bergen Exec VP Neil Dimick said. Bergen also wrote off $67 mil. for "doubtful receivables" from two long-term care customers
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth